Anika Therapeutics, Inc.

Equities

Market Closed - Nasdaq Other stock markets 04:00:00 2026-04-20 pm EDT			5-day change	1st Jan Change
15.82 ^USD	-1.12%		+6.25%	+64.62%

Apr. 16	Xilio Therapeutics, Inc. Announces Board Changes	CI
Apr. 08	Telix Pharmaceuticals Limited Announces Board Appointments, Effective May 11, 2026	CI

Published on 02/26/2026 at 01:35 pm EST - Modified on 02/26/2026 at 01:50 pm EST

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Good morning, ladies and gentlemen, and welcome to Anika's Fourth Quarter and Year-End Earnings Conference Call. [Operator Instructions] This call is

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Apr. 16	Xilio Therapeutics, Inc. Announces Board Changes	CI
Apr. 08	Telix Pharmaceuticals Limited Announces Board Appointments, Effective May 11, 2026	CI
Mar. 03	Tranche Update on Anika Therapeutics, Inc.'s Equity Buyback Plan announced on May 28, 2024.	CI
Feb. 27	Barrington Adjusts Price Target on Anika Therapeutics to $17 From $16, Maintains Outperform Rating	MT
Feb. 27	B. Riley Adjusts Price Target on Anika Therapeutics to $18 From $16, Maintains Buy Rating	MT
Feb. 26	Anika Therapeutics, Inc., Q4 2025 Earnings Call, Feb 26, 2026
Feb. 26	Anika Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
Feb. 26	Anika Therapeutics, Inc. Provides Earnings Guidance for the Full Year 2026	CI
Jan. 08	Anika Therapeutics Appoints CFO Stephen Griffin as Chief Executive Officer	MT
Jan. 08	Anika Therapeutics, Inc. Announces Executive Changes	CI
Jan. 08	Anika Therapeutics, Inc. Announces Chief Executive Officer Changes	CI
Nov. 05	Tranche Update on Anika Therapeutics, Inc.'s Equity Buyback Plan announced on May 28, 2024.	CI
Nov. 05	Anika Therapeutics, Inc., Q3 2025 Earnings Call, Nov 05, 2025
Nov. 05	Anika Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
Nov. 05	Anika beats Q3 revenue estimates, maintains guidance	RE